Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor base. | ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive scarring of lung ...

Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on PLRX stock, giving a Buy rating on January 15.Stay Ahead of ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

The therapy showed a ‘favourable’ safety profile both as a single agent and in combination with standard-of-care treatment.

With the daily environmental pollution taking a massive toll on our lungs as evidenced by the poor air quality index (AQI) of ...